Last reviewed · How we verify
Conventional Antiarrhythmic Drug Therapy
Conventional antiarrhythmic drugs work by modulating cardiac electrical activity through various mechanisms including sodium channel blockade, beta-adrenergic antagonism, potassium channel inhibition, or calcium channel blockade to restore normal heart rhythm.
Conventional antiarrhythmic drugs work by modulating cardiac electrical activity through various mechanisms including sodium channel blockade, beta-adrenergic antagonism, potassium channel inhibition, or calcium channel blockade to restore normal heart rhythm. Used for Atrial fibrillation management, Ventricular arrhythmias, Supraventricular tachycardia.
At a glance
| Generic name | Conventional Antiarrhythmic Drug Therapy |
|---|---|
| Sponsor | Population Health Research Institute |
| Drug class | Antiarrhythmic agent (mixed class) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Conventional antiarrhythmic drugs are classified into four main groups (Vaughan-Williams classification) that target different aspects of cardiac electrophysiology. Class I agents block sodium channels to slow conduction, Class II agents are beta-blockers that reduce automaticity, Class III agents block potassium channels to prolong repolarization, and Class IV agents block calcium channels to slow AV nodal conduction. These mechanisms collectively suppress ectopic activity and restore normal sinus rhythm in patients with various arrhythmias.
Approved indications
- Atrial fibrillation management
- Ventricular arrhythmias
- Supraventricular tachycardia
Common side effects
- Proarrhythmia
- Hypotension
- Bradycardia
- Dizziness
- Fatigue
- Nausea
Key clinical trials
- Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease (NA)
- CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction) (NA)
- Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial Fibrillation (NA)
- Development and Polit Study of Get Ready With my Heart Program (NA)
- Dose Escalation for SBRT of Recurrent VT Ventricular Tachyarrhythmia - a Single Center, Phase II Clinical Trial (PHASE1)
- Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF (NA)
- Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation (NA)
- A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |